Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Moderna fell sharply in pre-open trading after announcing that its norovirus vaccine candidate mRNA-1403 failed to meet early success criteria in a Phase 3 interim analysis. The disappointment came despite second-quarter revenue that topped consensus, and was compounded by a roughly $0.9 billion charge to 2026 cost of sales tied to litigation and a…
Telus shares tumbled sharply in pre-market trading after the company reported Q2 2026 results and announced a 55% cut to its quarterly dividend, removal of a dividend reinvestment plan discount, a revenue guidance downgrade, and a three-point strategic plan under incoming CEO Victor Dodig aimed at accelerating debt reduction and refocusing capital …
At age 80, Luiz Inacio Lula da Silva will formally accept his seventh and likely final presidential nomination at the Workers Party convention, heading into a rare moment of unity among Brazil’s center-left. For the first time in nearly four decades, all five major center-left parties have rallied behind a single presidential ticket. That consolida…
TransAlta Corporation announced its Q2 2026 financial results showcasing strong operational performance and positive net earnings compared to the prior year loss. The company highlighted progress on strategic projects including a major acquisition in Colorado and energy transition efforts. Despite challenging Alberta market conditions, TransAlta ac…
U.S.-backed negotiations between Venezuela's interim government and a segment of the opposition are set to commence on Saturday without the country's most prominent opposition leader, Maria Corina Machado. The sessions aim to overhaul political institutions ahead of future elections and underscore Washington's heightened role in Venezuelan politics…
Ocugen, Inc., a US biotech company specializing in gene therapies for blindness, announced upcoming presentations at two major August 2026 investor conferences. The company will discuss its modifier gene therapy platform designed to address multiple gene networks involved in blindness-related diseases like retinitis pigmentosa and geographic atroph…
GCL Global Holdings Ltd. announced its fiscal year 2026 results, showcasing a 68.2% increase in revenues driven by the expansion of its gaming distribution and publishing operations. Despite strong revenue growth to $238.9 million, the company reported a net loss of $26.2 million due to substantial one-time expenses related to acquisitions and plat…
Tenax Therapeutics announced its second quarter financial results for 2026 and updated investors on its clinical progress, including the expectation of topline data from its Phase 3 LEVEL clinical trial for PH-HFpEF in August 2026. The company reported increased R&D expenses due to ongoing Phase 3 trials and has $118 million in cash, extending its …
INmune Bio Inc., a late-stage biotechnology firm, announced receipt of about $4.6 million in non-dilutive research and development rebates from Australia and the UK. These incentives bolster the company’s cash position, exceed its quarterly operating cash used, and support ongoing development and regulatory filing efforts for its lead drug candidat…
Werewolf Therapeutics announced its second quarter 2026 financial results highlighted by a $21 million asset sale to Jazz Pharmaceuticals, repayment of debt, and a net income of $3.7 million compared to a loss last year. The company maintains a cash runway into Q2 2027 and is exploring strategic alternatives with Piper Sandler while progressing its…
Tiziana Life Sciences announced PET imaging results from the third Multiple System Atrophy patient treated with its lead candidate, intranasal foralumab, showing significant reductions in neuroinflammation in key brain regions. These consistent findings across patients strengthen confidence in foralumab's potential to modulate neuroinflammation and…
Balchem Corporation reported strong financial results for Q2 2026, achieving record quarterly net sales of $284 million, net earnings of $44.6 million, and adjusted EBITDA of $77.9 million, marking impressive year-over-year growth. The company experienced robust sales and earnings growth in all three business segments: Human Nutrition and Health, A…
INmune Bio Inc., a late-stage biotechnology company focused on inflammation and immunology, announced it will report its second quarter 2026 financial results on August 6th, 2026, followed by a conference call and webcast. The company will also provide updates on its two late-stage product platforms—CORDStrom™, targeting regulatory filings in 2026,…
Regeneron Pharmaceuticals announced the recipients of the 2026 Regeneron Prize for Creative Innovation, awarding $150,000 in total to early-career scientists for their innovative proposals in biomedical research. The prize supports scientific creativity and future health breakthroughs, aligning with Regeneron's commitment to fostering STEM educatio…
Shares of Marvell Technology and Astera Labs rose in pre-market trading after Amazon reported that its AI and chips businesses have reached $25 billion in annual run rates. The disclosure, accompanying a fifth straight quarter of cloud sales growth for Amazon, prompted positive market moves for companies exposed to cloud infrastructure spending and…
Perella Weinberg Partners reported a 1% increase in revenues for Q2 2026 compared to the previous year while showing a 17% revenue decline for the first half of the year, affected by lower fee events. The firm continues to invest in talent, adding multiple senior partners and directors, and anticipates closing the acquisition of Gleacher Shacklock …
Perella Weinberg Partners announced the promotion of eight managing directors to partner status, recognizing their contributions in sectors including financial services, industrials, healthcare, and technology. The moves reflect confidence in their leadership to advance the firm's global advisory capabilities across multiple offices.
Penguin Solutions reported a blowout Q3 with 48% revenue growth to $479M and raised full-year guidance, signaling durable demand for its memory and AI infrastructure products. Valuation is elevated but supported by accelerating gross margins and pricing power as memory supply tightness benefits vendors focused on AI workloads. We outline a mid-term…
Brookfield Renewable Partners L.P. announced strong Q2 2026 financial results, including record Funds From Operations (FFO) of $421 million, a 13% year-over-year increase per unit. The company delivered significant new renewable capacity, expanded its battery storage platform through acquisition of Aypa, and continued to optimize capital structure …
SK hynix has been punished with a cascade of weak sentiment that looks priced for a worst-case memory depression. I upgrade to Buy: this is a tactical, data-driven play on improving DRAM/NAND fundamentals, inventory destocking ending, and an easily imaginable earnings rebound. Trade plan included with exact entry, stop and target for a mid-term swi…
Brookfield Business Corporation reported solid financial results for Q2 2026, driven by increases in adjusted EBITDA across its Industrials and Business Services segments. The company generated over $1.2 billion in proceeds from asset sales and distributions year-to-date, including the sale of Multiplex. Brookfield continued investing in growth via…
Bullish, a NYSE-listed global digital asset platform, announced it will release its Q2 2026 financial results on August 13, 2026, and host an earnings conference call the same day. The company provides institutional digital asset market infrastructure and information services, including Bullish Exchange and CoinDesk media and analytics. Details on …
Veeva's recent pullback after a solid Q1 print looks like an opportunity. The company reported EPS of $2.24 and revenue of $882.95M on 06/03/2026, raised FY2027 guidance, and sits on healthy cash flow. At the same time the stock trades at elevated multiples and investors have priced strong future growth. We rate VEEV a buy from $201.54 with a defin…
This week exposed three core investor anxieties: whether the AI investment binge can be sustained, how the expanding conflict in the Middle East will affect energy flows, and whether recent central bank messaging has undermined monetary credibility. Semiconductor and cloud earnings produced mixed signals; a surprise regional military escalation sen…
European Union regulators have given the green light to Saudi Arabia's Public Investment Fund and its consortium for the $55 billion acquisition of Electronic Arts, approving the transaction under the bloc's rules on foreign subsidies. Electronic Arts reported it had received all required regulatory approvals as of July 30 and reiterated its expect…
